Therapy Areas: Inflammatory Diseases
TikoMed AB enters into strategic collaboration with IQVIA
6 May 2022 -

TikoMed AB, a Sweden-based biopharmaceutical company, and United States-based clinical research services company IQVIA announced on Thursday that they have entered into a strategic collaboration with the aim of expediting the development of TikoMed's lead drug platform candidate ILB, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation.

The partnership is intended to support TikoMed's clinical development, regulatory and commercial strategies. IQVIA said that it provides its therapeutic expertise, data and technology alongside flexible operating models to enable biopharma organisations such as TikoMed to expedite the clinical development and commercialisation of innovative products that improve patient lives.

The Connecting Architects advised TikoMed on this strategic collaboration.

Login
Username:

Password: